The AI revolution is significantly outpacing the IC industry’s ability to sufficiently test multi-chip systems for all necessary failure mechanisms at probe, final test, and system-level test. The ...

Drs. Tina Lockwood and Stacy Gray share the newly released evidence-based guideline on circulating tumor DNA (ctDNA) testing from ASCO. They highlight recommendations on when ctDNA testing should be ...

FromSoftware's Nintendo Switch 2 exclusive, The Duskbloods, is still slated to arrive this year. We don't have a release date as yet — I'm hoping FromSoft has the guts to try counterprogramming Grand ...

From the moment 4-year-old Cameron first stepped out into Glimmer in Spyro 2, he knew video games were going to play a central role in the rest of his life. Though he never planned to make it the ...

New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has highlighted the value of minimal residual disease (MRD) testing in ...

David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spread ...

CHICAGO -- Adding a multicancer early detection (MCED) blood test to standard of care did not reduce the number of cancers detected at stage III or IV across a dozen tumor types for which no screening ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning. By ...

Cancer is complex, and treatment decisions increasingly depend on complete molecular information. GTC’s platform analyzes both DNA and RNA to help identify clinically meaningful biomarkers that more ...

Genomic Testing Cooperative, a molecular diagnostics company advancing comprehensive cancer profiling through DNA and RNA analysis, will exhibit and present research at the 2026 American Society of ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key ...